Cycle guidelines Cycle guidelines Approach Phase 2 reference Duration 48 weeks Review Point Every 4 weeks at each dose step Best For Matches the original NEJM trial structure Approach Phase 3 TRIUMPH reference Duration 68-72 weeks Review Point Every 4 weeks
Tirzepatide is a dual GIP/GLP-1 receptor agonist, which the platform describes as its compounded alternative to Zepbound and Mounjaro
Clean the injection site with an alcohol swab and allow it to air dry completely before proceeding
But it does hint to the possibility that GLP-1 medications like Ozempic, Wegovy and Mounjaro could have more than just weight loss and blood glucose management properties
What should I do if I miss a Wegovy dose
For suspected loss of efficacy: Verify medication storage, handling, and injection technique Review adherence patterns and timing of doses Assess for other factors affecting treatment response (dietary changes, new medications, intercurrent illness) Consider dose optimization within approved ranges if not already at maximum dose Evaluate alternative explanations for treatment failure If treatment failure persists despite addressing these factors, options include: Switching to an alternative GLP-1 receptor agonist (semaglutide, dulaglutide) or other therapy For diabetes management: considering ADA-recommended alternatives such as metformin optimization, SGLT2 inhibitors, or basal insulin For weight management: exploring other FDA-approved anti-obesity medications Intensifying lifestyle interventions and behavioral support For suspected hypersensitivity reactions: Immediate discontinuation of tirzepatide is warranted for any signs of serious hypersensitivity, including urticaria, angioedema, difficulty breathing, or anaphylaxis
